Boris Pasche, President and CEO of Karmanos Cancer Institute, shared a post on LinkedIn:
“In a groundbreaking report, Jimenez et al. demonstrate that glioblastoma-specific frequencies identified by the TheraBionic research team can effectively block the growth of glioblastoma. The study reveals that these frequencies exhibit antitumor activity in patients with brain tumors.
Key findings include:
- CACNA1H, also known as the Cav3.2 T-type gated calcium channel, acts as the bioantenna on glioblastoma cells, sensing these specific frequencies.
- Upon activation, CACNA1H leads to calcium influx, disrupts the mitotic spindle, and activates the Mitotic Roles of Polo-like kinase pathway.
Notably, CACNA1H has been recognized as the same bioantenna across three different tumor types: breast cancer, hepatocellular carcinoma, and glioblastoma.
For further details, you can access the full report.”
Title: Treatment of glioblastoma with tumor-specific amplitude-modulated radiofrequency electromagnetic fields
Authors: Hugo Jimenez, Denise Gibo, Sambad Sharma, Michael Pennison, Lance D. Miller, Minghui Wang, Kimberly Sheffield, Liyue Zhang, Allan Johansen, Preeya Achari, Callum Mcgrath, Sean Lester, Jason Tang, Kojo Agyemang, Annette Johnson, Christopher T. Whitlow, Michael Chan, Kounosuke Watabe, Ralph D’Agostino Jr., Janaka Liyanage, Asfar Azmi, Geoffrey Barger, Alexandre Barbault, Glenn J. Lesser, Waldemar Debinski, Boris C. Pasche
Read the Full Article.
More from Boris Pasche on OncoDaily.